Manchester,U.K. – in a landmark achievement for genetic medicine, a young boy in England has become the first patient globally to be treated for Hunter syndrome with a novel gene therapy utilizing stem cells. The groundbreaking, one-time treatment, administered at Royal Manchester Children’s Hospital, offers a possibly curative option to ongoing enzyme replacement therapies for the devastating inherited disorder. Developed by researchers at the University of Manchester, the therapy represents a meaningful advance in the fight against rare genetic diseases and a beacon of hope for affected families worldwide.
A three-year-old boy battling Hunter syndrome has become the first person in the world to receive gene therapy using stem cells to treat the rare genetic disorder.
Hunter syndrome, also known as mucopolysaccharidosis II (MPS II), is a rare inherited condition that progressively damages the body and brain. It typically affects children, with symptoms often appearing between the ages of 10 and 20.
The groundbreaking treatment, developed over more than a decade at the University of Manchester, was administered at Royal Manchester Children’s Hospital (RMCH). The boy received the gene therapy in February 2025, and has been showing steady improvement in the months following the procedure.
Specialists utilized a one-time gene therapy approach. They extracted stem cells from the child and, in a laboratory setting, corrected the faulty gene responsible for the disease. These modified cells were then reintroduced into the patient’s system, where they began producing the missing enzyme crucial for breaking down complex sugars.
The therapy aims to address the neurological aspects of Hunter syndrome by clearing the buildup of toxic sugars in the brain, with the hope of preventing or halting the progression of cognitive decline. This innovative approach represents a significant step forward in treating devastating genetic conditions.
Currently, stem cell-based treatment offers a potential alternative to enzyme replacement therapy, which can be costly – approximately £375,000 per year – and requires lifelong weekly infusions. This new therapy could significantly reduce the long-term burden of treatment for patients and families.
This development offers hope for individuals with rare genetic diseases and highlights the potential of gene therapy to transform medical care. You can learn more about this breakthrough here.
#genetherapy #HealthTech #TechhubUpdate
